UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

**Form 10-QSB**

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934               For the quarter ended March 31, 2003

[   ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934               For the transition period from ________ to __________

Commission File Number:  **1-1115**

**BOSTON PACIFIC MEDICAL, INC.**

(Exact name of Registrant as specified in charter)

|**MASSACHUSETTS**                                            | **04-3053538**          
|------------------------------------------------------------ | ------------------------
|State or other jurisdiction of incorporation or organization | I.R.S. Employer I.D. No.

**428 EAST 790 SOUTH, PLEASANT GROVE, UT  84062**

(Address of principal executive offices)             (Zip Code)

Issuer's telephone number, including area code:  **(801) 785-2328**

Check whether the Issuer (1) has filed all reports required to be filed by section 13 or 15(d) of the Exchange Act during the
past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to
such fling requirements for the past 90 days.  (1)  Yes [   ]  No [X]       (2)  Yes  [X]    No  [  ]

State the number of shares outstanding of each of the Issuer's classes of common equity as of the latest practicable date: At
May 13, 2003, there were 15,000,000 shares of the Registrant's Common Stock outstanding.

**PART I**

**ITEM 1.  FINANCIAL STATEMENTS**

The condensed financial statements included herein have been prepared by the Company, without audit, pursuant to the
rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally
included in financial statements prepared in accordance with generally accepted accounting principles have been condensed
or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make
the information presented not misleading.

In the opinion of the Company, all adjustments, consisting of only normal recurring adjustments, necessary to present
fairly the financial position of the Company as of March 31, 2003, and the results of its operations and changes in its
financial position from January 1, 1996, through March 31, 2003, have been made.  The results of its operations for such
interim period is not necessarily indicative of the results to be expected for the entire year.  These condensed financial
statements should be read in conjunction with the financial statements and notes thereto included in the Company's annual
report on Form 10-KSB for the year ended December 31, 2002.

**BOSTON PACIFIC MEDICAL, INC.**

**(Development Stage Company)**

**BALANCE SHEETS**

**March 31, 2003 and December 31, 2002**

****    ******
**Mar 31,**
**Dec 31,****2003**
**2002****ASSETS****CURRENT ASSETS**Cash
$       -
$        -___________
___________Total Current Assets
$       -
$        -==========
==========**LIABILITIES AND
STOCKHOLDERS' EQUITY****CURRENT LIABILITIES**Accounts payable - related party
$ 13,378
$ 4,921Accounts payable
4,074
7,151___________
___________Total Current Liabilities
17,452
12,072___________
___________**STOCKHOLDERS' EQUITY** **-**(deficiency)****Preferred stock221,037 shares authorized at
$1.00 par value; 20,000 shares issued
and outstanding
20,000
20,000Common stock15,000,000 shares authorized  at
$0.01 par value; 15,000,000 shares
issued and outstanding
150,000
150,000Capital in excess of par value - dated
January 1, 1996  - note 1
(150,000)
(150,000)Deficit accumulated during
development stage - dated January 1,
1996 - note 1
(37,452)
(32,072)___________
___________Total Stockholders' Equity -
(deficiency)
(17,452)
(12,072)___________
___________$         -
$         -==========
==========The accompanying notes are an integral part of these financial statements.

**BOSTON PACIFIC MEDICAL, INC.**

**(Development Stage Company)**

**STATEMENT OF OPERATIONS**

**For the Three Months Ended March 31, 2003 and 2002 and the Period**

**January 1, 1996 (date of inception of development stage) to March 31, 2003************
**Mar 31,**
**Mar 31,**
**Jan 1, 1996******
**2003**
**2002**
**to Mar 31, 2003****REVENUES**
$       -
$    -
$       -**EXPENSES**
5,380
-
37,452___________
___________
___________**NET LOSS**
$ (5,380)
$   -
$ (37,452)==========
==========
==========**NET LOSS PER
COMMON SHARE******Basic
$     -
$    -==========
==========**AVERAGE
OUTSTANDING SHARES**(stated in 1000's)****Basic
15,000
15,000==========
==========The accompanying notes are an integral part of these financial statements.

****

**BOSTON PACIFIC MEDICAL, INC.**

**(Development Stage Company)**

**STATEMENT OF CASH FLOWS**

**For the Three Months Ended March 31, 2003 and 2002 and the Period******

**January 1, 1996 (date of inception of development stage) to March 31, 2003****

********
**Mar 31,**
**Mar 31,**
**Jan 1, 1996 to******       ****
**2003**
**2002**
**to Mar 31, 2003****CASH FLOWS FROM
OPERATING
ACTIVITIES**Net loss
$ (5,380)
$     -
$ (37,452)Adjustments to
reconcile net loss to net cash
provided by operating
activitiesChanges in accounts
payable
5,380
-
17,452___________
___________
___________Net Change in Cash From
Operations
-
-
(20,000)___________
___________
___________**CASH FLOWS FROM
INVESTING
ACTIVITIES**
-
-
-**CASH FLOWS FROM
FINANCING
ACTIVITIES**Proceeds from issuance
of common stock
-
-
20,000___________
___________
___________Net Change in Cash
-
-
-Cash at Beginning of Period
-
-
-___________
___________
___________Cash at End of Period
$      -
$     -
$     -==========
==========
==========The accompanying notes are an integral part of these financial statements.

**BOSTON PACIFIC MEDICAL, INC.**

**( Development Stage Company )**

**NOTES TO FINANCIAL STATEMENTS**

**March 31, 2003**

**1. ORGANIZATION**

The Company was incorporated under the laws of the state of Massachusetts on  June 12, 1989 with the name "Boston &
Pacific Company Inc." with authorized common capital stock of 200,000  shares with  par value of $1.00 and preferred
stock of 100,000 shares with a par value of $2.45.There have been several changes in the authorized common and preferred
stock and name changes and on July 7, 1993 the   authorized was increased to 15,000,000 common shares with a par value
of $.01 and 221,037 preferred shares with a par value of $1.00 and on July 30, 2002 the name was changed to "Boston
Pacific Medical, Inc." The terms of the preferred shares include conversion rights of 60.5 shares of common for each share
of preferred at any time after 90 days of the issuance of the preferred, at the option of the holder, which would amount to
1,210,000 additional common shares issued.  The voting rights of the preferred is 60.5 votes for each share of preferred.
The liquidation rights of the preferred include a preference of $.01 per share plus any unpaid declared dividends after any
senior rights. There has been no preferred dividends declared. The Company will have the obligation to increase the
authorized common stock, if necessary, to satisfy  the terms of the preferred.

For the years prior to January 1, 1996 the Company completed several acquisitions and divestitures of subsidiaries and
during 1995 transferred all its remaining assets in exchange for the assumption of its liabilities as part of a divestiture of its
remaining subsidiary and the Company then became inactive. Prior to January 1, 1996 the Company and its subsidiaries
reported their operations as a consolidated group and have been unable to separate the accumulated operating deficit of the
Company from its former subsidiaries. On  January 1, 1996  the  management of the Company  completed a recapitalization
of the Company by adjusting  the accumulated deficit to zero with a corresponding  adjustment to the excess over par value
account, with the statement of operations to begin on that date. The Company is considered to be in the development stage
after that date.

**2.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

Accounting Methods

The Company recognizes income and expenses based on the accrual method of accounting.

Dividend Policy

The Company has not yet adopted a policy regarding payment of dividends.

Financial Instruments

The carrying amounts of financial instruments, including accounts payable,  are considered by management to be their
estimated fair values.

**BOSTON PACIFIC MEDICAL, INC.**

**( Development  Stage Company )**

**NOTES TO FINANCIAL STATEMENTS (Continued)**

**March 31, 2003**

**2.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued**

Income Taxes

On March 31, 2003, the Company  had a  net operating loss available for carry forward of  $78,668. The tax benefit of
approximately $23,600 from the carryforward  has been fully offset by a valuation reserve because the use of the future tax
benefit is doubtful since the Company has no operations.  The  net operating loss will expire starting  in  2005 through
2023.

Basic and Diluted Net Income (Loss) Per Share

Basic net income (loss) per share amounts are computed based on the weighted average number of shares actually
outstanding. Diluted net income (loss) per share amounts are computed using the weighted average number of common
shares and common equivalent shares outstanding as if shares had been issued on the exercise of the preferred share rights
unless the  exercise becomes  antidilutive  and then only the basic per share amounts are shown in the report.

Financial and Concentrations Risk

The Company does not have any concentration or related financial credit risk.

Revenue Recognition

Revenue is recognized on the sale and delivery of product or the completion of  services provided.

Statement of Cash Flows

For the purposes of the statement of cash flows, the Company considers all highly liquid investments with a maturity of
three months or less to be cash equivalents.

Estimates and Assumptions

Management uses estimates and assumptions in preparing financial statements in accordance with generally accepted
accounting principles.  Those estimates and assumptions affect the reported amounts of the assets  and liabilities, the
disclosure of contingent assets and liabilities, and the reported revenues and expenses.  Actual results could vary from the
estimates that were assumed in preparing these financial statements.

**BOSTON PACIFIC MEDICAL, INC.**

**( Development  Stage Company )**

**NOTES TO FINANCIAL STATEMENTS (Continued)**

**March 31, 2003**

**2.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued**

Recent Accounting Pronouncements

The Company does not expect that the adoption of other recent accounting pronouncements will have a material impact on
its  financial statements.

**3.  SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES**

Officers-directors and their controlled companies have acquired 63% of the common stock of the Company.

An affiliate of the Company (by common officers) has made demand, no interest loans to the Company of $13,378.

**4.  GOING CONCERN**

The Company does not have the working capital necessary  for its planned activity and to service its debt,  which raises
substantial doubt about its ability to continue as a going concern.

Continuation of the Company as a going concern is dependent upon obtaining additional working capital and the
management of the Company has developed a strategy, which it believes will accomplish this objective through additional
loans from related parties, and equity funding,  which will enable the Company to operate for the coming year.

**ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION**

The Company is a development stage company and has had no material operations since approximately 1995.  The
Company does not have any significant cash or other material assets, nor does it have an established source of revenues
sufficient to cover operating costs and to allow it to continue as a going concern.  The Company intends to take advantage
of any reasonable business proposal presented which management believes will provide the Company and its stockholders
with a viable business opportunity.  The board of directors will make the final approval in determining whether to complete
any acquisition.

The cash requirements for the current year have been approximately $6,000.  These funds have been advanced by one of
the shareholders.  Management estimates that the cash requirements for the year ending December 31, 2003, will be a like
amount, if no change in operations occurs during the year.  These expenses are primarily for legal and accounting fees in
connection with the preparation and filing of the Company's periodic reports.  There are no agreements with any person and
no assurance that all or a portion of these funds will be loaned to the Company.  If the Company is unable to borrow such
funds, management will seek other sources of funding which are currently unknown to management.  There is no assurance
that such funding would be available, or that if it is made available, it could be obtained on terms favorable to the
Company.

The investigation of specific business opportunities and the negotiation, drafting, and execution of relevant agreements,
disclosure documents, and other instruments will require substantial management time and attention and will require the
Company to incur costs for payment of accountants, attorneys, and others.  If a decision is made not to participate in or
complete the acquisition of a specific business opportunity, the costs incurred in a related investigation will not be
recoverable.  Further, even if an agreement is reached for the participation in a specific business opportunity by way of
investment or otherwise, the failure to consummate the particular transaction may result in the loss to the Company of all
related costs incurred.

Currently, management is not able to determine the time or resources that will be necessary to locate and acquire or merge
with a business prospect.  There is no assurance that the Company will be able to acquire an interest in any such prospects,
products, or opportunities that may exist or that any activity of the Company, regardless of the completion of any
transaction, will be profitable.  If and when the Company locates a business opportunity, management of the Company will
give consideration to the dollar amount of that entity's profitable operations and the adequacy of its working capital in
determining the terms and conditions under which the Company would consummate such an acquisition.  Potential
business opportunities, no matter which form they may take, will most likely result in substantial dilution for the
Company's shareholders due to the likely increase in the authorized shares, or the possible reverse split of outstanding
shares, and issuance of stock to acquire such an opportunity.

**ITEM 3.  CONTROLS AND PROCEDURES**

Within 90 days prior to the filing date of this report, the Company's management, consisting of a sole officer, Brant Dees,
conducted an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and
procedures. Based on this evaluation, Mr. Dees, the president and principal financial officer, concluded that the Company's
disclosure controls and procedures are effective. There have been no significant changes in the Company's internal controls
or in other factors that could significantly affect those controls subsequent to the date of our last evaluation.

**PART II**

**ITEM 5.  OTHER INFORMATION**

Series B Preferred Stock

On April 11, 2003, the Board of Directors authorized the creation of a Series B Preferred stock, consisting of 10,000 shares
of the authorized preferred stock of the Company.  The new series is not convertible into common stock of the Company.
The holders of the Series B Preferred Stock have 1,300 votes per share of the Preferred Stock and are entitled to vote on
any and all matters brought to a vote of shareholders of Common Stock.  In the event of any liquidation, dissolution or
winding up of the Company, holders of shares of the Series B Preferred Stock are entitled to receive, out of legally
available assets, a liquidation preference of $1.00 per share, plus an amount equal to any accrued and unpaid dividends to
the payment date. Outstanding shares of Series B Preferred Stock are not subject to redemption by the Company. The
designation, number of, voting powers, designations, preferences, limitations, restrictions and relative rights of the Series B
Preferred Stock may be amended by a resolution of the Board of Directors.

The Company issued 10,000 shares of the Series B Preferred Stock on April 11, 2003, to Capital Holdings, LLC for prior
consulting services rendered to the Company.

Reverse Stock Split

On May 5, 2003, at a special meeting of shareholders of the Company, shareholders holding shares representing a majority
of the votes authorized a reverse split of the outstanding common shares of the Company at the rate of one share for each
100 shares outstanding, provided that no shareholder would be reduced to fewer than 100 shares.  At the meeting,
9,376,000 common shares voted for the reverse split and 13,000,000 votes by the holder of the Series B Preferred Stock
were cast for the reverse split.  No shares voted against the proposed stock split and no shares abstained from voting.  The
reverse split was declared effective on May 5, 2003.  As a result of the reverse stock split, the Company will have
approximately 159,521 common shares outstanding.

Change of Domicile

On May 5, 2003, at the special meeting of shareholders of the Company, shareholders holding shares representing a
majority of the votes authorized a change of domicile of the Company from the Commonwealth of Massachusetts to the
State of Nevada.  In connection with the change of domicile, the shareholders also approved the following changes to the
Nevada corporation formed for the purpose of the changing the domicile: (i) a name change to DirectView, Inc.; (ii) an
increase the number of authorized shares of common stock from 15,000,000 to 300,000,000, with a change in the par value
of the common stock to $.0001 per share; and (iii) an increase in the number of authorized shares of preferred stock from
221,037 to 5,000,000, with a change in the par value to $.0001.  At the meeting, 9,376,000 common shares voted for the
reverse split and 13,000,000 votes by the holder of the Series B Preferred Stock were cast for the reverse split.  No shares
voted against the proposed stock split and no shares abstained from voting.

In anticipation of the change of domicile, on April 11, 2003, the Company incorporated a Nevada corporation by the name
of Boston Pacific Medical, Inc. as a wholly owned subsidiary of the Company (the "Nevada Company").  Also on April 11,
2003, the Company and the Nevada Company entered into a Plan and Agreement of Merger to effect the change of
domicile.  The agreement provides that on the effective date of the merger the Company would be merged into the Nevada
Company as the surviving entity, with the name and capitalization changes authorized by the shareholders.  Each share of
post-reverse split common stock of the Company would be exchanged for one share of the common stock of the Nevada
Company on the effective date of the merger.  Each outstanding share of 8% Convertible Preferred Stock would be
converted into one share of 8% Convertible Preferred Stock of the Nevada Company with the same rights and preferences
as the same series of preferred stock of the Massachusetts company, except that rather than being convertible into 60.5
common shares, these preferred shares would be convertible into 500 common shares, and would have voting rights equal
to the conversion rate of this series.  Each outstanding share of Series B Preferred Stock would be converted into one share
of Series B Preferred Stock of the Nevada Company with the same rights and preferences as the same series of preferred
stock of the Massachusetts company.

Management anticipates that the change of domicile will be effective on or about May 15, 2003.

Proposed Reverse Acquisition of Ralston Communication, Inc.

On April 10, 2003, the Company entered into a letter of intent with Ralston Communications, Inc., a Florida corporation
providing video, audio, multipoint videoconferencing, document conferencing, data and IP videoconferencing services. The
parties anticipate issuing 107,776,566 post-reverse split shares for all of the outstanding stock of Ralston and changing
management of the Company to persons designated by Ralston.  Management anticipates that closing of the transaction will
occur on or about May 16, 2003.

**ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K**

(a) Exhibits.  The following exhibit is attached to this report:

3.1 Articles of Incorporation of the Nevada Company filed on April 11, 2003

3.2 Bylaws of the Nevada Company

3.3 Agreement and Plan of Merger dated April 11, 2003

3.4 Articles of Merger of the Nevada Company

4.1 Designation of Rights for the 8% Convertible Preferred Stock of the Nevada Company

4.2 Designation of Rights for the Series B Preferred Stock of the Nevada Company

99.1 Written Statement of the Chief Executive Officer and Principal Financial Officer with respect to compliance with
Section 13(a) of the Securities Exchange Act of 1934.

(b) Reports on Form 8-K:  No reports on Form 8-K were filed during the first quarter of the fiscal year ending December
31, 2003.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly authorized.

Boston Pacific Medical, Inc.

Date:  May 14, 2003     By: /s/ Brant Dees

Brant Dees, President and Principal

Financial and Accounting Officer

CERTIFICATION

I, Brant Dees, certify that:

1.  I have reviewed this quarterly report on Form 10-QSB of Boston Pacific Medical, Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made,
not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly
present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for,
the periods presented in this quarterly report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a-14 and 15-d-14) for the registrant and I have:

(a) designed such disclosure controls and procedures to ensure the material information relating to the registrant is made
known to me, particularly during the period in which this quarterly report was being prepared;

(b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the
filing date of this quarterly report (the "Evaluation Date"); and

(c) presented in this quarterly report my conclusions about the effectiveness of the disclosure controls and procedures
based on our evaluation as of the Evaluation Date;

5. I have disclosed, based on my most recent evaluation, to the registrant's auditors and to the boards of directors:

(a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's
ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material
weaknesses in internal controls; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant's internal controls; and

6. I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other
factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any
corrective actions with regard to significant deficiencies and material weaknesses.

Date:  May 14, 2003

/s/ Brant Dees

Brant Dees, Chief Executive Officer and Principal Financial Officer**